Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.
Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- Check5 days agoChange DetectedThe expanded-access record for upadacitinib is displayed, with study details, conditions, participation criteria, intervention information, and sponsor contact details. Previously, the page showed a 403 error.SummaryDifference39%
- Check12 days agoChange DetectedThe ClinicalTrials.gov site revision label changes from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%
- Check19 days agoChange DetectedA site-wide banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%
- Check26 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%
- Check33 days agoChange DetectedThe revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%
- Check54 days agoChange Detected403 Forbidden error now replaces the study record content, blocking access to the trial’s details and related information. The deletions indicate that a substantial amount of trial content was removed from the page, leaving only basic navigation and the footer visible.SummaryDifference16%
Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.